Within 2 decades of onset, 80% of untreated patients with relapsing-remitting multiple sclerosis (MS) convert to a phase of irreversible disability accrual termed secondary progressive MS. The association between disease-modifying treatments (DMTs), and this conversion has rarely been studied and never using a validated definition.
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis / Brown, J William L; Coles, Alasdair; Horakova, Dana; Havrdova, Eva; Izquierdo, Guillermo; Prat, Alexandre; Girard, Marc; Duquette, Pierre; Trojano, Maria; Lugaresi, Alessandra; Bergamaschi, Roberto; Grammond, Pierre; Alroughani, Raed; Hupperts, Raymond; McCombe, Pamela; Van Pesch, Vincent; Sola, Patrizia; Ferraro, Diana; Grand'Maison, Francois; Terzi, Murat; Lechner-Scott, Jeannette; Flechter, Schlomo; Slee, Mark; Shaygannejad, Vahid; Pucci, Eugenio; Granella, Franco; Jokubaitis, Vilija; Willis, Mark; Rice, Claire; Scolding, Neil; Wilkins, Alastair; Pearson, Owen R; Ziemssen, Tjalf; Hutchinson, Michael; Harding, Katharine; Jones, Joanne; McGuigan, Christopher; Butzkueven, Helmut; Kalincik, Tomas; Robertson, Neil. - In: JAMA. - ISSN 0098-7484. - 321:2(2019), pp. 175-187. [10.1001/jama.2018.20588]
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis
Ferraro, Diana;
2019
Abstract
Within 2 decades of onset, 80% of untreated patients with relapsing-remitting multiple sclerosis (MS) convert to a phase of irreversible disability accrual termed secondary progressive MS. The association between disease-modifying treatments (DMTs), and this conversion has rarely been studied and never using a validated definition.
| File | Dimensione | Formato | |
|---|---|---|---|
|
jama_brown_2019_oi_180152.pdf
Open access
Tipologia:
Versione pubblicata dall'editore
Dimensione
626.05 kB
Formato
Adobe PDF
|
626.05 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
